Your browser is no longer supported. Please, upgrade your browser.
Settings
IMNP Immune Pharmaceuticals Inc. daily Stock Chart
IMNP [NASD]
Immune Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-2.16 Insider Own4.00% Shs Outstand32.02M Perf Week-39.16%
Market Cap6.74M Forward P/E- EPS next Y-0.43 Insider Trans4.06% Shs Float30.63M Perf Month-38.45%
Income-26.60M PEG- EPS next Q-0.21 Inst Own1.80% Short Float2.92% Perf Quarter-49.58%
Sales- P/S- EPS this Y76.40% Inst Trans-18.06% Short Ratio1.50 Perf Half Y-75.18%
Book/sh0.31 P/B0.68 EPS next Y- ROA-104.00% Target Price- Perf Year-91.55%
Cash/sh0.08 P/C2.50 EPS next 5Y- ROE-431.10% 52W Range0.24 - 3.43 Perf YTD-63.05%
Dividend- P/FCF- EPS past 5Y46.60% ROI- 52W High-93.86% Beta1.58
Dividend %- Quick Ratio0.30 Sales past 5Y- Gross Margin- 52W Low-12.33% ATR0.03
Employees7 Current Ratio0.30 Sales Q/Q- Oper. Margin- RSI (14)19.26 Volatility18.65% 8.88%
OptionableNo Debt/Eq0.49 EPS Q/Q65.70% Profit Margin- Rel Volume2.33 Prev Close0.25
ShortableYes LT Debt/Eq0.15 EarningsApr 11 BMO Payout- Avg Volume595.20K Price0.21
Recom- SMA20-36.30% SMA50-39.14% SMA200-72.62% Volume1,388,081 Change-16.63%
Jan-05-18Initiated Maxim Group Buy $3
Oct-13-15Reiterated Chardan Capital Markets Buy $5 → $6.50
Oct-08-15Initiated ROTH Capital Buy $6
May-18-15Reiterated Chardan Capital Markets Buy $5 → $6
Mar-09-15Initiated Chardan Capital Markets Buy $5.50
May-15-18 09:00AM  Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid GlobeNewswire -23.35%
May-07-18 08:30AM  Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc. GlobeNewswire
08:25AM  Market Trends Toward New Normal in The AES, Immune Pharmaceuticals, Hercules Capital, Zendesk, Chevron, and Cornerstone OnDemand Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Apr-10-18 07:40AM  Wired News Johnson & Johnson to Pay Compensatory Damages over Claims Linking Cancer to Asbestos in Talc ACCESSWIRE
Apr-02-18 05:20PM  Immune Pharmaceuticals Announces 2017 Financial Results Marketwired
Mar-12-18 12:46PM  Interested In Immune Pharmaceuticals Inc (NASDAQ:IMNP)? Heres How It Performed Recently Simply Wall St.
08:00AM  Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium Marketwired
Mar-05-18 08:15AM  Research Report Identifies CarGurus, Peabody Energy, Brighthouse Financial, CPI Card Group, Alcoa, and Immune Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-02-18 01:07PM  Immune Pharmaceuticals Incs (NASDAQ:IMNP) Profit Outlook Simply Wall St.
Feb-27-18 08:00AM  Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders ACCESSWIRE -6.60%
Feb-20-18 07:30AM  Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update ACCESSWIRE -14.62%
Feb-06-18 08:00AM  Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018 ACCESSWIRE
Jan-26-18 08:00AM  Immune Pharmaceuticals Announces Adjournment of Annual Meeting ACCESSWIRE
Jan-23-18 09:00AM  Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018 ACCESSWIRE
Jan-10-18 11:15AM  Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018 ACCESSWIRE +13.67%
Jan-06-18 01:30PM  What Are The Drivers Of Immune Pharmaceuticals Incs (NASDAQ:IMNP) Risks? Simply Wall St.
Jan-04-18 09:00AM  Immune Pharmaceuticals to Present at the Biotech Showcase(TM) Annual Conference on January 10, 2018 ACCESSWIRE
Dec-14-17 02:05PM  Is Immune Pharmaceuticals Incs (NASDAQ:IMNP) CEO Salary Justified? Simply Wall St.
Dec-11-17 11:00AM  Immune Pharmaceuticals Appoints John Zhang, MD, Ph.D. as Vice President, Research and Development ACCESSWIRE
Dec-05-17 12:35PM  Does Immune Pharmaceuticals Incs (IMNP) Past Performance Indicate A Stronger Future? Simply Wall St.
Dec-04-17 07:10AM  Wired News Pfizer Announced an Agreement to Develop and Commercialize Basileas Antifungal CRESEMBA in China and the Asia/ Pacific Region ACCESSWIRE
Nov-15-17 08:34AM  Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update Business Wire
Nov-04-17 07:29PM  Should You Invest In The Healthcare Stock Immune Pharmaceuticals Inc (IMNP)? Simply Wall St.
Oct-31-17 07:45AM  Consolidated Research: 2018 Summary Expectations for Columbia Property Trust, Dr Pepper Snapple, Immune Pharmaceuticals, Air Products and Chemicals, Box, and ACADIA Pharma Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-23-17 12:09PM  Immune Pharmaceuticals Inc. Announces Closing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants Business Wire
Oct-20-17 04:16PM  What You Must Know About Immune Pharmaceuticals Incs (IMNP) Major Investors Simply Wall St.
08:10AM  Today's Research Reports on Stocks to Watch: Corbus Pharmaceuticals and Immune Pharmaceuticals ACCESSWIRE
Oct-19-17 09:00AM  Immune Pharmaceuticals Inc. Announces Pricing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants Business Wire -37.42%
Oct-11-17 08:45AM  Immune Pharmaceuticals Announces Presentation at The Liver Meeting 2017 Business Wire +13.37%
Oct-06-17 08:10AM  Immune Exits Oncology and Narrows Its Focus on Two Promising Drugs ACCESSWIRE
Oct-04-17 12:46PM  What Kind Of Risk And Return Should You Expect For Immune Pharmaceuticals Inc (IMNP)? Simply Wall St.
Sep-28-17 08:20AM  Today's Research Reports on Stocks to Watch: Therapix Biosciences and Immune Pharmaceuticals ACCESSWIRE
Sep-27-17 08:21AM  Immune Pharmaceuticals shares surge 75% on positive mid-stage clinical trial results MarketWatch +16.67%
08:00AM  Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid Business Wire
Aug-29-17 04:15PM  Immune Pharmaceuticals Receives NASDAQ Letter Business Wire
Aug-28-17 08:00AM  Immune Pharmaceuticals Provides R&D and Business Update and Summary of Recent Financial Highlights Business Wire
Aug-24-17 08:00AM  Today's Research Reports on Trending Tickers: Intra-Cellular Therapies and Immune Pharmaceuticals ACCESSWIRE -34.09%
Aug-14-17 08:00AM  Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer Business Wire
Aug-09-17 09:30AM  CYTOVIA Inc, IMMUNE Pharmas Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic Properties of Its Lead Drug Ceplene® and Filing of a New Worldwide Patent Business Wire
Aug-07-17 09:27AM  CYTOVIA Inc., IMMUNE Pharmas Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene® in Chronic Myeloid Leukemia (CML) Business Wire
Aug-04-17 10:16AM  Immune Pharmaceuticals, Inc. Issues Letter to Shareholders Business Wire -20.51%
Jul-19-17 09:32AM  Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company Business Wire -7.44%
Jul-13-17 07:30AM  IMMUNE Pharmaceuticals Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with Mutated NPM1 Business Wire
Jul-11-17 01:45PM  Cytovia Inc, Immune Pharmaceuticals Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America Business Wire
Jul-05-17 08:30AM  IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal PR Newswire
Jun-29-17 08:30AM  Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of Ceplene® in Latin America PR Newswire +8.42%
Jun-20-17 09:14AM  Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML) PR Newswire +5.77%
Jun-19-17 08:30AM  Immune Receives NASDAQ Compliance Letter PR Newswire +5.26%
Jun-15-17 09:28AM  Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene PR Newswire
May-26-17 08:30AM  Immune Receives Nasdaq Letters PR Newswire
May-04-17 09:00AM  Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million PR Newswire
Apr-24-17 08:41AM  Immune Pharma shares tumble 9% premarket as it unveils restructuring MarketWatch -20.96%
08:30AM  Immune Pharmaceuticals Announces Corporate Restructuring PR Newswire
08:15AM  Immune Receives Nasdaq Letter PR Newswire
Apr-21-17 07:30AM  Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Immune Pharmaceuticals Accesswire
Apr-20-17 10:25AM  Why Immune Pharmaceuticals Shares Are Skyrocketing 24/7 Wall St. +49.59%
09:07AM  Immune Pharma's stock rockets on heavy volume after license pact MarketWatch
08:00AM  Immune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding License and Commercializion of Ceplene® in Latin America PR Newswire
Apr-12-17 07:30AM  Immune Pharmaceuticals Announces 1-for-20 Reverse Stock Split PR Newswire -5.48%
Mar-23-17 06:06AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Mar-13-17 05:11PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events
09:55AM  Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement PR Newswire
Feb-28-17 08:30AM  Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid PR Newswire -5.31%
Feb-17-17 09:15AM  Immune Pharmaceuticals Announces the launch of REMAIN , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia PR Newswire
Feb-15-17 04:30PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-06-17 08:15AM  Blog Coverage Pfizer Signs Agreement with Citibank to Repurchase $5 Billion Worth of Shares Accesswire
07:20AM  Purcell Julie & Lefkowitz LLP Is Investigating Immune Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Feb-03-17 05:29PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -5.76%
Feb-01-17 04:03PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers +5.21%
Jan-27-17 07:00AM  Immune Pharmaceuticals Appoints New Chairman of the Board of Directors PR Newswire
Jan-23-17 08:45AM  Immune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment PR Newswire
Jan-19-17 04:02PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events -6.13%
Jan-17-17 09:10AM  Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI PR Newswire
Jan-09-17 06:11PM  Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq's Minimum Bid Price Rule PR Newswire
05:26PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Dec-22-16 04:51PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-20-16 04:09PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Dec-16-16 06:03AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
Nov-26-16 01:04PM  IMMUNE PHARMACEUTICALS INC Financials
Nov-22-16 09:00AM  Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016 PR Newswire
06:02AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan
Nov-18-16 04:11PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -5.00%
Nov-17-16 09:15AM  Immune Pharmaceuticals Secures Up to $11 Million in New Financing to be Deployed With a Focus on Bertilimumab Clinical Development PR Newswire +5.26%
Nov-08-16 04:03PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Oct-28-16 11:20AM  Here Are Three Big Biotech Movers And Our Take On Whats Next at Insider Monkey -12.69%
Oct-27-16 07:00AM  Immune Pharmaceuticals Receives FDA Guidance for Phase III Pivotal Trial of its AML Therapy Ceplene® In Combination with Low Dose IL-2 PR Newswire +38.00%
Oct-17-16 09:23AM  Immune Pharmaceuticals Announces Formation of Management Team for Maxim Pharmaceuticals, its Pain and Neurology Subsidiary PR Newswire
Sep-16-16 07:58AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St -10.34%
07:30AM  Immune Pharmaceuticals Signs Agreement to Fund Maxim Pharmaceuticals, Inc., its Pain and Neurology subsidiary PR Newswire
Sep-07-16 07:33AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E +14.55%
07:30AM  Immune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share PR Newswire
Aug-18-16 12:29PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Aug-16-16 07:30AM  Immune Pharmaceuticals Provides Business and R&D Update and Announces Second Quarter 2016 Financial Results PR Newswire
Aug-15-16 05:29PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-05-16 02:15AM  Immune Pharmaceuticals Inc (IMNP) CEO Daniel Gedeon Teper Bought $356,250 of Stocks +15.15%
Aug-03-16 09:27AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
Jul-19-16 05:09PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Of -10.36%
09:30AM  IMMUNE Pharmaceuticals to Form Pain and Neurology Spin Off Company around AmiKet PR Newswire
Jul-06-16 05:26PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases. It also develops NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, which is in preclinical stage for the treatment of atopic dermatitis and psoriasis. The company's immuno-oncology pipeline includes Ceplene for the maintenance of remission in patients with acute myeloid leukemia, which is in Phase III clinical trial in the United States and has approved in European Union; Crolibulin, a small molecule vascular disrupting agents (VDA) and apoptosis inducer that is in Phase II clinical trial for the treatment of patients with solid tumors; Azixa, a Phase II microtubular destabilizer that functions as a VDA; NanomAbs, a preclinical stage antibody-drug conjugate platform that allows the targeted delivery of combinations of chemotherapeutics into cancer cells; and bispecific antibodies, which are in preclinical stage against immune-oncology targets. In addition, it develops AmiKet, a prescription topical analgesic cream that has completed II clinical trials for the treatment of neuropathic pain; and LidoPAIN, an adhesive-backed, lidocaine-based patch that is in Phase II clinical trial for the treatment of acute lower back pain. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fiorino Anthony S.Chief Medical Officer and COOMay 17Buy0.2650,00012,90050,000May 18 03:32 PM